Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 793 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in... May 20, 2021 EMA Recommends Granting a Marketing Authorisation for Catumaxomab November 12, 2024 How to Stay Connected When Your Partner Has Cancer May 11, 2022 Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours February 10, 2026 Load more HOT NEWS Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline Breast Cancer Risk Genes Color-Blind Groom Sees Color For First Time After Bride Surprises Him... Cómo los ensayos clínicos pueden llevar a un tratamiento que salve...
